Araştırma Makalesi
BibTex RIS Kaynak Göster

Recombinant human G-CSF production as a protein based drug candidate for hematology and oncology

Yıl 2019, Cilt: 3 Sayı: 2, 92 - 100, 31.12.2019

Yasemin Bozkurt Sema Bilgin Seçil Erden İsmail Furkan Turan İsa Gökçe

https://doi.org/10.32571/ijct.600180
Cited By: 1

Öz

The human granulocyte colony stimulating factor
(hG-CSF) is a member of the CSF family. The first purpose of this study was production of
recombinant human G-CSF (rhG-CSF) which is an important therapeutic protein for
angiogenesis based clinical applicaitons. rhG-CSF was produced as
inclusion body in the Escherichia coli
strain BL21 (DE3) pLysE with pTOLT vector system. The rhG-CSF was purified by
Ni-NTA agarose afinity chromatography and characterized with SDS-PAGE analysis.
The effects of this therapeutic protein on cell
viability was measured by MTT assay. Additionally,  angiogenic potential of produced rhG-CSF
was investigated via HUVEC cell line by in vitro scratch assay.  As
a result, the purified protein induced cell proliferation and the EC50 value of protein based drug candidate was 0.051 mM. Additionally, it was determined that the migration ability of
the HUVECs was promoted by rhG-CSF in a concentration-dependent manner by in vitro scratch assay.  

Anahtar Kelimeler

Granulocyte colony stimulating factor recombinant proteins angiogenesis cell proliferation

Destekleyen Kurum

Tokat Gaziosmanpasa University Scientific Research Project

Proje Numarası

2016/61

Teşekkür

This study was financially supported by the Tokat Gaziosmanpasa University Scientific Research Project (2016/61). Additionally, Yasemin BOZKURT was supported by TUBİTAK-BİDEB 2210/C National Scholarship Program for MSc students.

Kaynakça

  • 1. Krasevec, N.; Milunovic, T.; Lasnik, M. A.; Lukancic, I.; Komel, R.; Gaberc Porekar, V. Acta Chim. Slov. 2014, 61, 709-717.
  • 2. Carlsson, G.; Åhlin, A.; Dahllöf, G.; Elinder, G.; Henter, J. I.; Palmblad, J. Brit. J. Haematol. 2004, 126 (1), 127-132.
  • 3. Jiang, Y.; Jiang, W.; Qiu, Y., Dai, W.; J. Hematol. Oncol. 2011, 4, 1-8.
  • 4. Hill, C. P.; Osslund, T. D.; Eisenberg, D. Proc. Natl. Acad. Sci. 1993, 90 (11), 5167-5171.
  • 5. Liu, X. L.; Hu, X.; Cai, W. X.; Lu, W. W.; Zheng, L. W., Biomed. Res. Int. 2016, 2016, 1-8.
  • 6. Bae, C. S.; Yang, D. S.; Chang, K. R.; Seong, B. L.; Lee, J. Biotechnol. Bioeng. 1998, 57 (5), 600-609.
  • 7. Hongbao, M.; Yan, Y.; Yiwu, S.; Ma, M. Stem Cell. 2011, 2(1), 36-65.
  • 8. Sivakumar, R. Immunome Res. 2014, 01 (s2), 1-8.
  • 9. Hüttmann, A.; Schirsafi, K.; Seeber, S.; Bojko, P. J. Cancer Res. Clin. Oncol. 2005, 131(3), 152-156.
  • 10. Kubota, N.; Orita, T.; Hattori, K.; Oh-Eda, M.; Ochi, N.; Yamazaki, T. J. Biochem. 1990, 107 (3), 486-492.
  • 11. Clogston, C. L.; Hu, S.; Boone, T. C.; Lu, H. S. J. Chromatogr. A, 1993, 637 (1), 55-62.
  • 12. Choi, J. H.; Keum, K. C.; Lee, S. Y. Chem. Eng. Sci. 2006, 61 (3), 876-885.
  • 13. Sivashanmugam, A.; Murray, V.; Cui, C.; Zhang, Y.; Wang, J.; Li, Q. Protein Sci. 2009, 18 (5), 936-948.
  • 14. Jana, S.; Deb, J. K. Appl. Microbiol. Biotechnol. 2005, 67 (3), 289-298.
  • 15. Vallejo, L. F.; Rinas, U. Microb. Cell Fact. 2004, 3, 1-12.
  • 16. Christopher, M. J.;. Link, D. C, J. Bone Miner. Res. 2008, 23 (11), 1765-1774.
  • 17. Babaeipour, V.; Khanchezar, S.; Mofid, M. R.; Abbas, M. P. H. Iran. Biomed. J. 2015. 19 (2), 102-110.
  • 18. Babaeipour, V.; Abbas, M. P. H.; Sahebnazar, Z.; Alizadeh, R. Bioproc. Biosyst. Eng. 2010, 33 (5), 591-598.
  • 19. Anderluh, G.; Gökçe, I.; Lakey, J. H. Protein Expres. Purif. 2003, 28 (1), 173-181.
  • 20. Gokce, I.; Anderluh, G.; Lakey, J.H. United States Patent et al. Patent No USOO7348408B2, 2008.
  • 21. Peymanfar, P.; Roghanian, R.; Ghaedi, K.; Sayed, H.; Yari, R. Int. J. Med. Biotechnol. Genet. 2016, 4 (2), 40-46.
  • 22. Tian, H.; Liu, C.; Gao, X.D.; Yao, W.B. World J. Microb. Biot. 2013, 29 (3), 505-13.
  • 23. Saeedinia, A.; Shamsara M.; Bahrami, A.; Zeinoddini, M.; Naseeri-Khalili, M. A. ; Mohammadi, R.; Sabet, N. M.; Sami, H. Biotechnology (Faisalabad), 2008, 7 (3), 569-573.
  • 24. Apte-Deshpande, A.; Somani, S.; Mandal, G.; Soorapaneni, S.; Padmanabhan, S. J. Biotechnol., 2009, 143 (1), 44-50.
  • 25. Adiredja, Y.; Fuad, A. M. Indones. J. Pharm. 2018, 29 (2), 94.
  • 26. Jin, H; Cantin, G.T.; Maki, S; Chew, L. C.; Resnick, S. M.; Ngai, J; Retallack, D. M. Protein Expr. Purif., 2011, 78(1), 69-77.
  • 27. Nair, N. R.; Chidambareswaren, M.; Manjula, S. Mol. Biotechnol. 2014, 56 (9), 849-862.
  • 28. Weber, K.; Pringle, J.; Osborn, M. Methods Enzymol. 1972, 26, 3-27.
  • 29. Cabrita, L. D.; Chow, M. K. M.; Bottomley, S. P. Biotechnol. Annu. Rev., 2004, 10 (1), 1-15.
  • 30. İnan, A.; İkiz, M.; Erden Tayhan, S.; Bilgin, S.; Genç, N.; Sayın, K.; Ceyhan, G.; Köse, M.; Dağ, A.; İspir, E. New J. Chem. 2018, 42 (4), 2952-2963.
  • 31. İnan, A.; Sünbül, A. B.; İkiz, M.; Erden Tayhan, S.; Bilgin, S.; Elmastaş, M.; Sayın, K.; Ceyhan, G.; Köse, M.; İspir, E. J. Organomet. Chem., 2018, 870,76-89.
  • 32. Liang, C. C.; Park, A. Y.; Guan, J. L. Nat. Protoc. 2007, 2(2), 329-333.
  • 33. Oh, J.; Hlatky, L.; Jeong, Y. S.; Kim, D. Toxins (Basel). 2016, 8 (7), 199.

Yıl 2019, Cilt: 3 Sayı: 2, 92 - 100, 31.12.2019

Yasemin Bozkurt Sema Bilgin Seçil Erden İsmail Furkan Turan İsa Gökçe

https://doi.org/10.32571/ijct.600180
Cited By: 1

Öz

Proje Numarası

2016/61

Kaynakça

  • 1. Krasevec, N.; Milunovic, T.; Lasnik, M. A.; Lukancic, I.; Komel, R.; Gaberc Porekar, V. Acta Chim. Slov. 2014, 61, 709-717.
  • 2. Carlsson, G.; Åhlin, A.; Dahllöf, G.; Elinder, G.; Henter, J. I.; Palmblad, J. Brit. J. Haematol. 2004, 126 (1), 127-132.
  • 3. Jiang, Y.; Jiang, W.; Qiu, Y., Dai, W.; J. Hematol. Oncol. 2011, 4, 1-8.
  • 4. Hill, C. P.; Osslund, T. D.; Eisenberg, D. Proc. Natl. Acad. Sci. 1993, 90 (11), 5167-5171.
  • 5. Liu, X. L.; Hu, X.; Cai, W. X.; Lu, W. W.; Zheng, L. W., Biomed. Res. Int. 2016, 2016, 1-8.
  • 6. Bae, C. S.; Yang, D. S.; Chang, K. R.; Seong, B. L.; Lee, J. Biotechnol. Bioeng. 1998, 57 (5), 600-609.
  • 7. Hongbao, M.; Yan, Y.; Yiwu, S.; Ma, M. Stem Cell. 2011, 2(1), 36-65.
  • 8. Sivakumar, R. Immunome Res. 2014, 01 (s2), 1-8.
  • 9. Hüttmann, A.; Schirsafi, K.; Seeber, S.; Bojko, P. J. Cancer Res. Clin. Oncol. 2005, 131(3), 152-156.
  • 10. Kubota, N.; Orita, T.; Hattori, K.; Oh-Eda, M.; Ochi, N.; Yamazaki, T. J. Biochem. 1990, 107 (3), 486-492.
  • 11. Clogston, C. L.; Hu, S.; Boone, T. C.; Lu, H. S. J. Chromatogr. A, 1993, 637 (1), 55-62.
  • 12. Choi, J. H.; Keum, K. C.; Lee, S. Y. Chem. Eng. Sci. 2006, 61 (3), 876-885.
  • 13. Sivashanmugam, A.; Murray, V.; Cui, C.; Zhang, Y.; Wang, J.; Li, Q. Protein Sci. 2009, 18 (5), 936-948.
  • 14. Jana, S.; Deb, J. K. Appl. Microbiol. Biotechnol. 2005, 67 (3), 289-298.
  • 15. Vallejo, L. F.; Rinas, U. Microb. Cell Fact. 2004, 3, 1-12.
  • 16. Christopher, M. J.;. Link, D. C, J. Bone Miner. Res. 2008, 23 (11), 1765-1774.
  • 17. Babaeipour, V.; Khanchezar, S.; Mofid, M. R.; Abbas, M. P. H. Iran. Biomed. J. 2015. 19 (2), 102-110.
  • 18. Babaeipour, V.; Abbas, M. P. H.; Sahebnazar, Z.; Alizadeh, R. Bioproc. Biosyst. Eng. 2010, 33 (5), 591-598.
  • 19. Anderluh, G.; Gökçe, I.; Lakey, J. H. Protein Expres. Purif. 2003, 28 (1), 173-181.
  • 20. Gokce, I.; Anderluh, G.; Lakey, J.H. United States Patent et al. Patent No USOO7348408B2, 2008.
  • 21. Peymanfar, P.; Roghanian, R.; Ghaedi, K.; Sayed, H.; Yari, R. Int. J. Med. Biotechnol. Genet. 2016, 4 (2), 40-46.
  • 22. Tian, H.; Liu, C.; Gao, X.D.; Yao, W.B. World J. Microb. Biot. 2013, 29 (3), 505-13.
  • 23. Saeedinia, A.; Shamsara M.; Bahrami, A.; Zeinoddini, M.; Naseeri-Khalili, M. A. ; Mohammadi, R.; Sabet, N. M.; Sami, H. Biotechnology (Faisalabad), 2008, 7 (3), 569-573.
  • 24. Apte-Deshpande, A.; Somani, S.; Mandal, G.; Soorapaneni, S.; Padmanabhan, S. J. Biotechnol., 2009, 143 (1), 44-50.
  • 25. Adiredja, Y.; Fuad, A. M. Indones. J. Pharm. 2018, 29 (2), 94.
  • 26. Jin, H; Cantin, G.T.; Maki, S; Chew, L. C.; Resnick, S. M.; Ngai, J; Retallack, D. M. Protein Expr. Purif., 2011, 78(1), 69-77.
  • 27. Nair, N. R.; Chidambareswaren, M.; Manjula, S. Mol. Biotechnol. 2014, 56 (9), 849-862.
  • 28. Weber, K.; Pringle, J.; Osborn, M. Methods Enzymol. 1972, 26, 3-27.
  • 29. Cabrita, L. D.; Chow, M. K. M.; Bottomley, S. P. Biotechnol. Annu. Rev., 2004, 10 (1), 1-15.
  • 30. İnan, A.; İkiz, M.; Erden Tayhan, S.; Bilgin, S.; Genç, N.; Sayın, K.; Ceyhan, G.; Köse, M.; Dağ, A.; İspir, E. New J. Chem. 2018, 42 (4), 2952-2963.
  • 31. İnan, A.; Sünbül, A. B.; İkiz, M.; Erden Tayhan, S.; Bilgin, S.; Elmastaş, M.; Sayın, K.; Ceyhan, G.; Köse, M.; İspir, E. J. Organomet. Chem., 2018, 870,76-89.
  • 32. Liang, C. C.; Park, A. Y.; Guan, J. L. Nat. Protoc. 2007, 2(2), 329-333.
  • 33. Oh, J.; Hlatky, L.; Jeong, Y. S.; Kim, D. Toxins (Basel). 2016, 8 (7), 199.
Toplam 33 adet kaynakça vardır.

Ayrıntılar

Birincil Dil İngilizce
Konular Kimya Mühendisliği
Bölüm Makale
Yazarlar

Yasemin Bozkurt Bu kişi benim 0000-0002-3456-3261

Sema Bilgin 0000-0001-5921-5434

Seçil Erden 0000-0001-8473-5896

İsmail Furkan Turan 0000-0002-2391-1582

İsa Gökçe Bu kişi benim 0000-0002-5023-9947

Proje Numarası 2016/61
Yayımlanma Tarihi 31 Aralık 2019
Yayımlandığı Sayı Yıl 2019 Cilt: 3 Sayı: 2

Kaynak Göster

APA Bozkurt, Y., Bilgin, S., Erden, S., Turan, İ. F., vd. (2019). Recombinant human G-CSF production as a protein based drug candidate for hematology and oncology. International Journal of Chemistry and Technology, 3(2), 92-100. https://doi.org/10.32571/ijct.600180
AMA Bozkurt Y, Bilgin S, Erden S, Turan İF, Gökçe İ. Recombinant human G-CSF production as a protein based drug candidate for hematology and oncology. Int. J. Chem. Technol. Aralık 2019;3(2):92-100. doi:10.32571/ijct.600180
Chicago Bozkurt, Yasemin, Sema Bilgin, Seçil Erden, İsmail Furkan Turan, ve İsa Gökçe. “Recombinant Human G-CSF Production As a Protein Based Drug Candidate for Hematology and Oncology”. International Journal of Chemistry and Technology 3, sy. 2 (Aralık 2019): 92-100. https://doi.org/10.32571/ijct.600180.
EndNote Bozkurt Y, Bilgin S, Erden S, Turan İF, Gökçe İ (01 Aralık 2019) Recombinant human G-CSF production as a protein based drug candidate for hematology and oncology. International Journal of Chemistry and Technology 3 2 92–100.
IEEE Y. Bozkurt, S. Bilgin, S. Erden, İ. F. Turan, ve İ. Gökçe, “Recombinant human G-CSF production as a protein based drug candidate for hematology and oncology”, Int. J. Chem. Technol., c. 3, sy. 2, ss. 92–100, 2019, doi: 10.32571/ijct.600180.
ISNAD Bozkurt, Yasemin vd. “Recombinant Human G-CSF Production As a Protein Based Drug Candidate for Hematology and Oncology”. International Journal of Chemistry and Technology 3/2 (Aralık 2019), 92-100. https://doi.org/10.32571/ijct.600180.
JAMA Bozkurt Y, Bilgin S, Erden S, Turan İF, Gökçe İ. Recombinant human G-CSF production as a protein based drug candidate for hematology and oncology. Int. J. Chem. Technol. 2019;3:92–100.
MLA Bozkurt, Yasemin vd. “Recombinant Human G-CSF Production As a Protein Based Drug Candidate for Hematology and Oncology”. International Journal of Chemistry and Technology, c. 3, sy. 2, 2019, ss. 92-100, doi:10.32571/ijct.600180.
Vancouver Bozkurt Y, Bilgin S, Erden S, Turan İF, Gökçe İ. Recombinant human G-CSF production as a protein based drug candidate for hematology and oncology. Int. J. Chem. Technol. 2019;3(2):92-100.

Cited By

Enhanced Biomass Production of Recombinant Pfu DNA Polymerase Producer Escherichia coli BL21(DE3) by Optimization of Induction Variables Using Response Surface Methodology
The Protein Journal
https://doi.org/10.1007/s10930-023-10122-8
 Kapak Resmi İndir

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.